360 万名医疗保险参保者可能有资格使用减肥药物 Wegovy，每年的费用可能高达 30 亿美元。 3.6 million Medicare enrollees may become eligible for Wegovy, an anti-obesity drug, with potential $3B annual cost.

根据 KFF 的分析，360 万名医疗保险参保者可能有资格享受减肥药物 Wegovy 的保险。 3.6 million Medicare enrollees may become eligible for coverage of Wegovy, an anti-obesity drug, according to a KFF analysis. FDA 批准 Wegovy 用于降低非糖尿病超重或肥胖成年人的心血管疾病风险。 The FDA approved Wegovy for reducing cardiovascular disease risk in overweight or obese adults without diabetes. 然而，医疗保险的预算可能会紧张，因为每年的费用可能接近 30 亿美元，并且导致所有受益人的 D 部分保费增加。 However, Medicare's budget may be strained as it could cost nearly $3 billion annually and contribute to higher Part D premiums for all beneficiaries.